Amantadine in the treatment of Parkinson's disease and other movement disorders.
Rascol O, Fabbri M, Poewe W.
Lancet Neurol. 2021 Dec;20(12):1048-1056. doi: 10.1016/S1474-4422(21)00249-0. Epub 2021 Oct 19.
PMID:34678171
Neuroprotective effects of amantadine for experimental acute carbon monoxide poisoning.
Zengin EN, Kayır S, Doğan G, Zengin M, Akdağlı Ekici A, Yalvaç M, Ayaz E, Özcan O, Karaca O, Yağan Ö, Alagöz A.
Eur Rev Med Pharmacol Sci. 2022 Oct;26(19):6919-6927. doi: 10.26355/eurrev_202210_29872.
PMID:36263571
Memantine for dementia.
McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, Maayan N, Ware J, Debarros J.
Cochrane Database Syst Rev. 2019 Mar 20;3(3):CD003154. doi: 10.1002/14651858.CD003154.pub6.
PMID:30891742
The Use of Amantadine in Treating Extrapyramidal Symptoms in Organophosphates Poisoning in a Child.
Althaqafi W, Alanazi RI, Almeshari WK.
Case Rep Pediatr. 2023 Sep 4;2023:1632052. doi: 10.1155/2023/1632052. eCollection 2023.
PMID:37700928
Amantadine use in the French prospective NS-Park cohort.
Fabbri M, Rousseau V, Corvol JC, Sommet A, Tubach F, De Rycke Y, Bertille N, Selvarasa Y, Carvalho S, Chaigneau V, Brefel-Courbon C, Ory-Magne F, Tessier S, Tir M, Bereau M, Meissner WG, Thiriez C, Marques A, Remy P, Schneider V, Moro E, Defebvre L, Houeto JL, Prange S, Eusebio A, Geny C, Frismand S, Damier P, Reuther CG, Castelnovo G, Benatru I, De Maindreville AD, Drapier S, Maltête D, Lagha-Boukbiza O, Rascol O; French N. S.-Park network.